http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP13012858-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2013-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fc1b58f4f9603395c75ae2c2c2b0c2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1de1ede11d052d5f921eec15214131d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de6be8cc84d79459d55ea96bb08b929e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b5ce6af00899c64f688384b241ad700 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f159f23260a4cb3774363aea583b37b2 |
| publicationDate | 2013-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EC-SP13012858-A |
| titleOfInvention | DERIVATIVES OF BRIDGED PIPERIDINE |
| abstract | The present invention relates to compounds of the formula: in which: heteroaryl I is a five or six link heteroaryl group, containing from 1 to 3 heteroatoms chosen from S and N; Hetaryl II is a six-link heteroaryl group, containing 1 to 3 heteroatoms chosen between S and N, or is a two-member cyclic system containing 1 to 4 heteroatoms chosen between S and N, of which at least a ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R2 is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, or is furyl, or is O-benzyl, - (CH2) p-phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkyl or by cyano; R3 is hydrogen or lower alkyl; Y is - (CH2) n-, -CH2OCH2-, -CH2O-, CH2S- , -CH2SCH2- and is attached to two of the carbon atoms of the ring, the union is made with the carbon atoms "a" and "b" of the ring or with the carbon atoms "c" and "d" of the ring ; p is the number 0 or 1; m is the number 0, 1 or 2; if m is 2, then R1 can be the same or different; n is the number 2 or 3; "o" is the number 0, 1 or 2, if "o" is 2, then R2 may be the same or different; or to its pharmaceutically active acid addition salts.The compounds present in the Formula I are beta-amyloid modulators and therefore may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease and other diseases, such as amyloid cerebral angiopathy , hereditary cerebral hemorrhage with Dutch amyloidosis (HCHWA-D), multi-infarct dementia, pugilistic dementia and Down syndrome. |
| priorityDate | 2011-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.